Strategic management of biotechnology agents.
The use of biologic response modifiers to demonstrate a value-driven approach to strategic management by pharmacists is described. To participate in decisions on the use of technology in their institutions, pharmacists must practice strategic management. This process includes environmental scanning, analysis of clinical and pharmacoeconomic data, and development of clinical management approaches. It is ideal for analyzing biologic response modifiers such as filgrastim and sargramostim. Emphasis must be placed on maximizing the fit among the products, the institution, and the health care environment. Pharmacists will find plentiful opportunities for clinical management with biotechnology agents. Practitioners who specialize in determining the total cost of care by using pharmacoeconomic methods are needed, as are practitioners trained to monitor the complicated biotechnology agents. Also, the institution needs to forecast accurately the impact of emerging biotechnology agents. If pharmacists can develop and control clinical, pharmacoeconomic, and reimbursement information databases for biotechnology agents, the pharmacy profession will be in a strong position to meet the challenges of biotechnology and realize the inherent opportunities.
Huber
S L
SL
Division of Pharmacy, University of Texas M.D. Anderson Cancer Center, Houston 77030.
D001709:Biotechnology / Q000639:trends*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D010595:Pharmacists; D010607:Pharmacy Service, Hospital / Q000191:economics*; D010934:Planning Techniques; D013223:Statistics as Topic
D007155:Immunologic Factors